Medicare Approves Add-On Payment for Bayesian Health AI Sepsis Monitor

Bayesian Health announced on September 2, 2026, that its continuous AI sepsis monitor was approved for a New Technology Add-on Payment (NTAP). [1] This Medicare mechanism temporarily reimburses hospitals for using qualifying new technologies, bridging the gap before standard payment rates incorporate the new costs. [1] The approval was granted under the Centers for Medicare and Medicaid Services’ fiscal year 2027 Inpatient Prospective Payment System final rule. [1]

Beginning October 1, 2026, hospitals using the device can bill for eligible use across adult Medicare fee-for-service inpatient admissions. [1] The company estimates this will span 739 diagnosis-related groups, which represent approximately 97 percent of all diagnosis-related groups in the inpatient prospective payment system. [1] Eligible discharges will qualify for an add-on payment of up to $61.84 per case, paid on a claim-by-claim basis without requiring separate authorization. [1] This temporary payment pathway remains in place for up to three years. [1]

The company described this approval as the first reimbursement pathway of its kind for pre-suspicion sepsis monitoring. [1] According to Bayesian Health, its product is now the first continuous sepsis monitoring technology to hold both FDA clearance and a dedicated Medicare reimbursement pathway. [1] The NTAP approval follows the device’s FDA clearance on April 30, 2026, as well as an earlier Breakthrough Device Designation from the agency. [1]

Securing a dedicated Medicare reimbursement pathway through NTAP removes a significant financial barrier for hospitals considering Bayesian Health's AI sepsis monitor. By offsetting the initial costs before standard claims data catches up, the company is positioned to drive faster adoption of its pre-suspicion monitoring technology across a vast majority of Medicare admissions. The dual achievement of FDA clearance and NTAP approval sets a high bar for competitors in the continuous monitoring space. What the sources don't address: How the specific $61.84 per-case payment compares to the actual per-patient cost of implementing and operating the Bayesian Health system.